JP2024538402A - アロマターゼ耐性ｅｒ＋がんのラソフォキシフェン処置 - Google Patents

アロマターゼ耐性ｅｒ＋がんのラソフォキシフェン処置 Download PDF

Info

Publication number
JP2024538402A
JP2024538402A JP2024529563A JP2024529563A JP2024538402A JP 2024538402 A JP2024538402 A JP 2024538402A JP 2024529563 A JP2024529563 A JP 2024529563A JP 2024529563 A JP2024529563 A JP 2024529563A JP 2024538402 A JP2024538402 A JP 2024538402A
Authority
JP
Japan
Prior art keywords
lasofoxifene
cancer
patient
inhibitor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538402A5 (enExample
Inventor
バリー サミュエル コム，
ジェフリー エル． グリーン，
Original Assignee
サーモニックス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーモニックス ファーマシューティカルズ， インコーポレイテッド filed Critical サーモニックス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024538402A publication Critical patent/JP2024538402A/ja
Publication of JP2024538402A5 publication Critical patent/JP2024538402A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024529563A 2021-11-18 2022-11-17 アロマターゼ耐性ｅｒ＋がんのラソフォキシフェン処置 Pending JP2024538402A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280769P 2021-11-18 2021-11-18
US63/280,769 2021-11-18
PCT/US2022/050218 WO2023091553A1 (en) 2021-11-18 2022-11-17 Lasofoxifene treatment of aromatase-resistant er+ cancer

Publications (2)

Publication Number Publication Date
JP2024538402A true JP2024538402A (ja) 2024-10-18
JP2024538402A5 JP2024538402A5 (enExample) 2025-11-26

Family

ID=79163840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529563A Pending JP2024538402A (ja) 2021-11-18 2022-11-17 アロマターゼ耐性ｅｒ＋がんのラソフォキシフェン処置

Country Status (12)

Country Link
US (3) US20230149350A1 (enExample)
EP (1) EP4433048A1 (enExample)
JP (1) JP2024538402A (enExample)
KR (1) KR20240132447A (enExample)
CN (1) CN118574612A (enExample)
AU (2) AU2022389457B2 (enExample)
CA (1) CA3238899A1 (enExample)
GB (1) GB202116903D0 (enExample)
IL (1) IL312895A (enExample)
MX (1) MX2024005959A (enExample)
TW (1) TW202333666A (enExample)
WO (1) WO2023091553A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909576T3 (es) 2016-10-11 2022-05-09 Univ Duke Tratamiento con lasofoxifeno del cáncer de mama ER+
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2025043004A1 (en) * 2023-08-21 2025-02-27 Duke University Treatment of solid cancer with lasofoxifene
WO2025075631A1 (en) * 2023-10-06 2025-04-10 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of endocrine therapy resistant er+ cancer
WO2025165887A1 (en) * 2024-01-30 2025-08-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199891A1 (en) * 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
JP2019529581A (ja) * 2016-10-11 2019-10-17 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
BR0108107A (pt) 2000-01-28 2003-03-11 Endorech Inc Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
WO2002056903A2 (en) 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
RU2278861C2 (ru) 2002-03-28 2006-06-27 Пфайзер Продактс Инк. Очищенный лазофоксифен и способ очистки рацемического лазофоксифена рекристаллизацией
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
CA2725390C (en) 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
WO2009137543A2 (en) 2008-05-06 2009-11-12 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
EP2239570A1 (en) 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
US20120052508A1 (en) 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
AU2012255920A1 (en) 2011-05-18 2013-11-07 Merck Sharp & Dohme Corp. Therapeutic anti-IGF1R combinations
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US20160030389A1 (en) 2013-03-13 2016-02-04 Alevere Medical Corporation Use of indole compounds for fat reduction and skin and soft tissue tightening
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
KR20170078811A (ko) 2014-11-07 2017-07-07 리폭센 테크놀로지즈 리미티드 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법
AU2016247674A1 (en) 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
WO2018071437A1 (en) 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
CN115737637A (zh) 2017-01-10 2023-03-07 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
CN107861293A (zh) * 2017-12-21 2018-03-30 惠科股份有限公司 液晶显示器及其背光模组
JP7571006B2 (ja) 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
EP4412649A4 (en) 2021-10-05 2025-11-05 Univ Duke Compositions containing small molecule tumor immunity regulators and their methods of use
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
JP2025517483A (ja) 2022-05-25 2025-06-05 サーモニックス ファーマシューティカルズ， インコーポレイテッド Ｃｄｋ４／６阻害剤で進行したｅｒ＋乳がんのラソフォキシフェン併用処置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529581A (ja) * 2016-10-11 2019-10-17 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
WO2019199891A1 (en) * 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENOR, G. ET AL.: "Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mu", MOLECULAR ONCOLOGY, vol. 14, no. 8, JPN6025051597, 2020, pages 1640 - 1652, ISSN: 0005754616 *
LAINE, M. ET AL.: "Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer", BREAST CANCER RESEARCH, vol. 23, no. 54, JPN6025051593, pages 1 - 12, ISSN: 0005754613 *
MOUABBI, J. A. ET AL.: "Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast", BREAST CANCER RESEARCH AND TREATMENT, vol. 190, JPN6025051594, 13 September 2021 (2021-09-13), pages 189 - 201, ISSN: 0005754614 *
NAGARAJ, G. AND MA, C. X.: "Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Re", ADVANCES IN THERAPY, vol. 38, JPN6025051595, 15 November 2020 (2020-11-15), pages 109 - 136, ISSN: 0005754615 *

Also Published As

Publication number Publication date
US20230321035A1 (en) 2023-10-12
WO2023091553A1 (en) 2023-05-25
CN118574612A (zh) 2024-08-30
IL312895A (en) 2024-07-01
US12023321B2 (en) 2024-07-02
US20230149350A1 (en) 2023-05-18
CA3238899A1 (en) 2023-05-25
US12433866B2 (en) 2025-10-07
AU2022389457B2 (en) 2024-12-19
AU2022389457A1 (en) 2024-07-04
US20240358677A1 (en) 2024-10-31
MX2024005959A (es) 2024-08-14
TW202333666A (zh) 2023-09-01
GB202116903D0 (en) 2022-01-05
KR20240132447A (ko) 2024-09-03
AU2025201821A1 (en) 2025-04-03
EP4433048A1 (en) 2024-09-25
AU2025201821B2 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
US12023321B2 (en) Lasofoxifene treatment of aromatase-resistant ER+cancer
AU2022246480B2 (en) Lasofoxifene treatment of ER+ breast cancer
WO2025075631A1 (en) Lasofoxifene treatment of endocrine therapy resistant er+ cancer
WO2025165887A1 (en) Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations
HK40077706A (en) Lasofoxifene treatment of er+ breast cancer
HK40005311B (en) Lasofoxifene treatment of er+ breast cancer
HK40005311A (en) Lasofoxifene treatment of er+ breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251117

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260402